xtandi
astellas pharma europe b.v. - enzalutamide - Простатни неоплазми - Ендокринна терапия - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
calumid, 50 mg film-coated tablets x 30 x 90
gedeon richter plc. - Бикалутамид -
bicalutamide kabi 50 mg film - coated tablets
fresenius kabi oncology plc. - 50 mg film - coated tablets
bicusan 50 mg film - coated tablets
actavis group ptc ehf. - 50 mg film - coated tablets
bicusan 150 mg film - coated tablets
actavis group ptc ehf. - 150 mg film - coated tablets
bicalodex 50 mg film - coated tablets
Чайкафарма Висококачествените лекарства АД - Бикалутамид - 50 mg film - coated tablets
bicalutamide accord 50 mg film - coated tablets
accord healthcare limited - Бикалутамид - 50 mg film - coated tablets
casodex 50 mg film - coated tablets
astrazeneca pharmaceuticals ab - Бикалутамид - 50 mg film - coated tablets
yonistib 50 mg film - coated tablets
НЕОЛА ФАРМА ЕООД - Бикалутамид - 50 mg film - coated tablets
calutide 50 mg film - coated tablets
МС ФАРМА АД, - Бикалутамид - 50 mg film - coated tablets